India, Nov. 10 -- Codexis Inc. (CDSX), an enzyme technology company, released data to validate the ECO Synthesis Manufacturing Platform to support the production of drugs designed using siRNA stereochemistry.
The company presented the data at the TIDES Europe 2026 conference.
Short interfering RNA (siRNA) are used to treat genetic diseases through the technique of RNA silencing. These therapies can be utilized to silence oncogenes and genes linked to inflammatory or autoimmune disorders.
The ECO Synthesis workflow was designed for optimal siRNA design, including by integration of tissue-targeting moieties. Data suggests that the manufactured siRNA therapeutics showed appropriate phosphorothioate stereochemistry, and a 3- to 4- fold incre...